Headline
Ingredion's recommended £2.7bn cash bid for TATE dominates a heavy capital-actions tape, while SBTX returns from suspension with restated accounts after a fabricated-revenue probe.
What UK Plc said today
No profit warnings landed. The standout is TATE: a recommended cash acquisition by Ingredion at 595p plus permitted dividends (up to 13.2p final, 6.8p interim), valuing the equity at ~£2.7bn and implied EV ~£3.7bn, with completion targeted for H2 2027 subject to antitrust. That sets a clean cross-Atlantic read for UK specialty ingredients valuations.
Results were a mixed bag. GENI delivered FY25 revenue of £3.1m (+14% YoY), gross margin up 6pts to 59%, but a wider adjusted EBITDA loss of £4.9m (vs £4.4m); management flagged Thermo Fisher distribution, a new FDA PMA submission targeted Q3 2026, and a first NHS ROCA contract at UCLH. SBTX is the day's governance story: HY26 revenue £2.17m (+37.4%) and a narrower £1.00m loss, but FY25 results were restated down from £4.64m to £3.87m after FRP Advisory identified fabricated royalty documentation by the former CEO; the FY25 adjusted loss roughly doubled to £2.13m and trading suspension was lifted only yesterday (7 June). ICG and RS1 filed annual report notices without numbers.
The sole trading update, HHV, reported a NAV total return of −7.79% in H1 with constructive commentary on a returning IPO pipeline — a small positive signal for UK small-cap risk appetite.
Statistical releases
- ONS UK Measures of National Well-being Dashboard (09:30) — refreshed framework data.
- ONS Beyond GDP insights, measures of National Well-being: June 2026 (09:30) — accompanying commentary release. Neither is market-moving.
Policy / monetary
Nothing from [BoE]. HMT was busy but thematic rather than market-moving: an AI Adoption Insights agreement from today's AI Adoption Summit, launch of the AI Economics Institute (prospectus + overview), the opening of the independent Access to Banking Services Review with a Call for Evidence, and HMRC doubling extra-support grant funding to £11m. The banking-access review is the one to track for retail-facing financials.
Themes
Capital returns and balance-sheet housekeeping dominate. Buybacks at HAS (raised to £10m), HLCL (up to £5m), OTB (up to £10m) and completion at WIX (£10m, 196.5p average) sit alongside a PEB capital reduction to create distributable reserves — boards are leaning into shareholder returns rather than capex. Debt issuance from LLOY (£750m 5.5% 2033 reset notes) and HMSO (€350m 3.875% 2031) shows term funding is open at sensible coupons.
Portfolio rationalisation is the other recurring note. MPAC disposed of Lambert for up to £20m to refocus on scalable packaging lines; BOOT sold 416 plots to Persimmon; BOOM terminated its strategic review citing undervaluation and upgraded H1 guidance to ≥US$45m revenue and ≥US$3m adjusted EBITDA; TGR launched a Portfolio Optimisation Programme alongside a board refresh. The connecting language is "scale" and "focus" — boards trimming long tails rather than acquiring breadth.
Governance remediation has a price. SBTX booked c.£0.7m of investigation costs; SMIN strengthened its board with Laurence Mulliez. Investors should expect more of this in micro-caps post-suspension.
Watch
- AXS preliminary results — 16 June 2026.
- NCYF investor presentation via IMC — 23 June 2026.
- BRCK completion of H.S. Jackson acquisition — on/around 30 June 2026.
- UMR Klein Aub completion — end June 2026.
- PEB capital reduction effective — 30 July 2026.
- MPAC Lambert disposal completion — Q3 2026, subject to NSIA clearance.
- GENI FDA PMA submission — Q3 2026; approval targeted Q4 2026.
- TATE/Ingredion scheme — expected effective H2 2027.